1Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? [J] Matrix Biol, 2002,21: 473-482.
2Miranda-Diaz A, Rincon AR, Salgado S, et al. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis[J]. Mol Ther, 2004,9:30-37.
3Solis-Herruzo JA, de la Torre P, Munoz-Yague MT. Hepatic stellate cells (HSC): architects of hepatic fibrosis[J]. Rev Esp Enferm Dig, 2003, 95: 438-439.
4Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation[J]. Med Gen Med, 2002,4: 27-30.
5Friedman SL. Liver fibrosis-from bench to bedside[J]. J Hepatol,2003,8(supple1): S38-S53.
6David KS, Alan BW. Liver fibrosis and inflammation. A review[J]. Annals of Hepatol, 2003, 2: 159-163.
7Mehra A, Wrana JL.TGF-beta and the Smad signal transduction pathway[J]. Biochem Cell Biol, 2002,80(5): 605-622.
8Wells RG, Fibrogenesis V. TGF-beta signaling pathways[J]. Am J Physiol Gastrointest Liver Physiol, 2000, 279: G845-G850.
9Heyninck K, Wullaert A, Beyaert R. Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease[J]. Biochem Pharmacol, 2003, 66: 1409-1415.
10Iimuro Y, Fujimoto J. Strategy of gene therapy for liver cirrohosis and hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2003, 10: 45-47.
